Related Experiment Videos
Tumor markers in endometriosis.
M S Abrão1, S Podgaec, J A Pinotti
1Department of Obstetrics and Gynecology, University of São Paulo, School of Medicine, Brazil. msabrao@ibm.net
Summary
Cancer antigen 125 (CA 125) is a key diagnostic marker for pelvic endometriosis, particularly stages III/IV. Blood samples collected during the first three days of the menstrual cycle improve CA 125 accuracy.
Area of Science:
- Gynecology
- Reproductive Medicine
- Onco-immunology
Background:
- Pelvic endometriosis is a common gynecological condition.
- Accurate diagnostic markers for endometriosis are crucial for timely intervention.
- Current diagnostic methods for endometriosis can be invasive and costly.
Purpose of the Study:
- To evaluate serum concentrations of various tumor markers in patients with pelvic endometriosis.
- To identify potential biomarkers for the diagnosis and staging of endometriosis.
Main Methods:
- Serum levels of CA 125, CA 15-3, CA 19-9, CEA, AFP, and B2MG were measured.
- Fifty women were studied: 35 with pelvic endometriosis and 15 controls.
- Blood samples were collected during the menstrual cycle and one week later.
Main Results:
- CA 125 concentrations were significantly altered in women with endometriosis.
- CEA, AFP, and B2MG levels remained normal in all patients.
- Minor, statistically insignificant variations were observed in CA 19-9 and CA 15-3.
Conclusions:
- CA 125 is the most significant marker for diagnosing stages III/IV endometriosis.
- Optimal timing for CA 125 measurement is during the initial 3 days of the menstrual cycle.
- Other tested tumor markers (CEA, AFP, B2MG, CA 15-3, CA 19-9) are not reliable for endometriosis diagnosis.